newsgathers

European Regulator Approves High-Dose Wegovy from Novo Nordisk

The European Medicines Agency (EMA) has given a positive recommendation for Novo Nordisk's elevated dose of Wegovy (semaglutide 7.2 mg). This higher dose has demonstrated an average weight loss of 20.7% over 72 weeks in individuals with obesity who do not have diabetes. The drug is also under review in other countries, including the U.S. These findings underscore Wegovy's potential in managing obesity and related health complications.